ContraFect_LOGO_Web.jpg
ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
30 mars 2020 05h00 HE | ContraFect Corporation
YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
18 mars 2020 07h00 HE | ContraFect Corporation
YONKERS, N.Y., March 18, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
04 mars 2020 07h00 HE | ContraFect Corporation
YONKERS, N.Y., March 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces One-for-Ten Reverse Stock Split
04 févr. 2020 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Feb. 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
03 févr. 2020 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
27 janv. 2020 07h00 HE | ContraFect Corporation
YONKERS, New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
13 janv. 2020 08h00 HE | ContraFect Corporation
YONKERS, N.Y., Jan. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
10 janv. 2020 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
20 déc. 2019 08h00 HE | ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
18 déc. 2019 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Dec. 18, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...